Evaluation of hydro-alcoholic extract of Eclipta alba for its multidrug resistance reversal potential: An in vitro study

Nutrition and Cancer

Volumn 65, Issue 5, 2013, Pages 775-780

  Chaudhary, Harshita ^a   Jena, Prasant Kumar ^a   Seshadri, Sriram ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; DOXORUBICIN; ECLIPTA PROSTRATA EXTRACT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; N (2 FLUORENYL)ACETAMIDE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CYTOTOXICITY; ECLIPTA PROSTRATA; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

2-ACETYLAMINOFLUORENE; AFLATOXIN B1; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ECLIPTA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIQUID-LIQUID EXTRACTION; LIVER NEOPLASMS; NEOPLASMS; P-GLYCOPROTEIN; PLANT EXTRACTS; TRANSFECTION; XENOBIOTICS;

EID: 84880397156     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.789116     Document Type: Article

References (26)

1. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Reviews Cancer 6, 674-687, 2006.
2. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Cancer Res 43, 2216-2218, 1976.
3. Leonard GD, Fojo T, and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8, 411-424, 2003.
4. Gottesman MM: Mechanisms of cancer drug resistance. Ann Rev Med 53, 615-627, 2002.
5. Castaing M, Brouant P, Loiseau A, Santelli-Rouvier C, Santelli M, et al.: Membrane permeation by multidrug-resistance-modulators and nonmodulators: effects of hydrophobicity and electric charge. J Pharm Pharmacol 52, 289-296, 2000.
6. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting Pglycoprotein. Cancer Control 10, 159-165, 2003.
7. Arcamone FM: From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 80, 201-206, 1998.
8. Chaudhary H, Dhuna V, Singh J, Kamboj SS, and Seshadri S: Evaluation of hydro-alcoholic extract of Eclipta alba for its anti-cancer potential: an in vitro study. J Ehnopharmacol 136, 363-367, 2011.
9. Chaudhary H, Arora R, Vora A, Jena PK, and Seshadri S: Evaluating the anti-cancer potential of hydro-alcoholic extract of Allium sativum L.: An in vitro and in vivo study. J Ethnobiol Traditional Med 117, 189-198, 2012.
10. Ananthi J, Prakasam A, and Pugalendi KV: Antihyperglycemic activity of Eclipta alba leaf on alloxan-induced diabetic rats. Yale J Biol Med 76, 97-102, 2003.
11. LeeMK, Ha NR, Yang H, Sung SH, Kim GH, et al.: Antiproliferative activity of triterpenoids from Ecliptaprostrata on hepatic stellate cells. Phytomed 15, 775-780, 2008.
12. Kumari CS, Govindasamy S, and Sukumar E: Lipid lowering activity of Ecliptaprostrata in experimental hyperlipidemia. J Ethnopharmacol 105, 332-335, 2006.
13. Saxena AK, Singh B, and Anand KK: Hepatoprotective effects of Eclipta alba on subcellular levels in rats. J Ethnopharmacol 40, 155-161, 1993.
14. Singh B, Saxena AK, Chandan BK, Agarwal SG, and Anand KK: In vivo hepatoprotective activity of active fraction from ethanolic extract of Eclipta alba leaves. Ind J Physiol Pharmacol 45, 435-441, 2001.
15. Dixit S and Achar M: Bhringaraja (Eclipta alba Linn.) In the treatment of infective hepatitis. Curr Med Pract 23, 237-242, 1979.
16. Dixit S andAchar M: Study of bhringaraja (Eclipta alba) therapy in jaundice in children. J Res Edu IndMed 2, 96-100, 1981.
17. Murphy RC, Hammarstrom S, SamuelssonB, and LeukotrieneC:Aslowreacting substance frommarinemastocytoma cells. The PNAS 76, 4275-4279, 1979.
18. Hill BA,Brown PC, Preisegger KH, and Silverman JA: Regulation ofmdr1b gene expression in Fischer,Wistar and Sprague-Dawley rats in vivo and in vitro. Carcinog 17, 451-457, 1996.
19. Gant TW, Silverman JA, Bisgaard HC, Burt RK,Marino PA, et al.: Regulation of 2-acetylaminofluorene and 3-methylcholajithrene-mediated induction of multidrug resistance and Regulation of rat mdrlb gene expression cytochrome P4501A gene family expression in primary hepatocyte cultures and rat liver. Molecular Carcinog 4, 499-509, 1991.
20. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, et al.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 39, 361-398, 1999.
21. Bradford MMN: A rapid and sensitive method forheguantation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 172, 248, 1976.
22. Liu H, Zang C, Fenner MH, Liu D, Possinger K, et al.: Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD 18. Blood 107, 3683-3692, 2006.
23. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54, 4833-4836, 1994.
24. Schrenk D, Gant TW, Michalke A, Orzechowski A, Silverman JA, et al.: Metabolic activation of 2-acetylaminofluorene is required for induction of multidrug resistance gene expression in rat liver cells. Carcinog 15, 2541-2546, 1994.
25. Thorgeirsson SS, Silverman JA, Gant TW, and Marino PA: Multidrug resistance gene family and chemical carcinogens. Pharmacol Ther 49, 283-292, 1991.
26. Ferry DR, Traunecker H, and Kerr DJ: Clinical trials of P-glycoprotein reversal in solid tumours. Euro J Cancer 32A, 1070-1081, 1996.